Market Exclusive

Insulet (NASDAQ:PODD) reported earnings of ($0.03) per share beating Walls Streets expectations.

Insulet (NASDAQ:PODD) reported Q2 2018 earnings this Afternoon, coming in at ($0.03) per share, beating Wall Street’s estimates of ($0.13) per Share. Revenue for the quarter came in at $124.26 million missing the streets estimates of $132.89 million Recent Insider Trading for Insulet (NASDAQ:PODD)

About Company Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.Recent Analyst Rating for Insulet (NASDAQ:PODD)

Recent Trading for Insulet (NASDAQ:PODD) Shares of Insulet closed the previous trading session at with shares trading hands.

Exit mobile version